Filing Details
- Accession Number:
- 0001567619-20-020759
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-08 16:03:06
- Reporting Period:
- 2020-12-04
- Accepted Time:
- 2020-12-08 16:03:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1676725 | Ideaya Biosciences Inc. | IDYA | Pharmaceutical Preparations (2834) | 474268251 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1790865 | Jason Throne | C/O Ideaya Biosciences, Inc. 7000 Shoreline Court, Suite 350 South San Francisco CA 94080 | Svp, General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-12-04 | 400 | $14.66 | 1,579 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-04 | 1,579 | $15.55 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades in prices ranging from $14.38 to $15.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Includes 1,979 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on November 30, 2020.
- This transaction was executed in multiple trades in prices ranging from $15.39 to $15.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Billionaire Hedge Funds
